Update to ACC/AHA Heart Failure Performance Measures; Quadruple Therapy and HF; ACEi, ARBs, and Chronic Kidney Disease
Release Date:
In this week’s View, Dr. Eagle looks at the 2024 update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure (HF). He then explores the eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed HF. Finally, Dr. Eagle discusses a systematic review of clinical trials investigating the use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARBs) for advanced chronic kidney disease (CKD). Subscribe to Eagle’s Eye View
Update to ACC/AHA Heart Failure Performance Measures; Quadruple Therapy and HF; ACEi, ARBs, and Chronic Kidney Disease